LI-RADS 2018版在CT上评估肝癌高危患者是否符合米兰标准肝移植资格的表现
本回顾性研究纳入136例肝癌高危患者,在肝移植前3个月内行肝脏方案CT,由两名放射科医师独立按LI-RADS v2018判读并构建OPTN分类,以移植肝病理为参考标准。LR-5对HCC的每病灶敏感度分别为55.9%和39.8%,阳性预测值分别为92.8%和86.5%;LI-RADS判定肝移植资格的准确率分别为92.7%和85.3%,OPTN标准分别为89.0%和84.4%。结论认为LI-RADS v2018在CT上对HCC检测具有高阳性预测值,对基于米兰标准的肝移植资格判定具有高准确率。
要点
- LR-5对HCC的阳性预测值读者1为92.8%、读者2为86.5%,敏感度分别为55.9%和39.8%。
- LI-RADS判定肝移植资格准确率读者1为92.7%、读者2为85.3%,OPTN标准分别为89.0%和84.4%。
- 术前LI-RADS评估的肝移植资格与移植后生存相关,5年总生存期符合米兰标准者92.2个月 vs 不适合移植者56.0个月。
核心结论
- LI-RADS v2018在CT上用于肝癌高危患者时,对HCC检测显示高阳性预测值,对基于米兰标准的肝移植资格判定显示高准确率,且基于术前LI-RADS评估的移植资格与移植后生存相关。
研究设计与样本
- 回顾性研究纳入136例肝癌高危患者(男110例、女26例,平均年龄53.9±8.1岁),在2010年1月至2018年12月间肝移植前3个月内行肝脏方案CT,由两名放射科医师独立按LI-RADS v2018判读并构建OPTN分类,以移植肝组织病理学分析为参考标准。
关键影像表现/征象
- 136例中组织病理学显示27例无恶性肿瘤、77例因HCC符合米兰标准而适合肝移植、32例不适合移植(其中16例HCC超出米兰标准、12例HCC伴大血管侵犯、4例非HCC恶性肿瘤)。
诊断标准与关键数值
- LR-5对HCC的每病灶敏感度读者1为55.9%、读者2为39.8%,阳性预测值读者1为92.8%、读者2为86.5%。
- 以LR-5观测代表HCC评估米兰标准时,LI-RADS判定肝移植资格的准确率读者1为92.7%、读者2为85.3%。
- OPTN标准判定肝移植资格的准确率读者1为89.0%、读者2为84.4%。
临床应用与阅片要点
- 作者结论支持在肝移植候选者评估中使用CT上的LI-RADS。
- 5年总生存期符合米兰标准者 vs 不适合移植者:LI-RADS为92.2个月 vs 56.0个月,OPTN标准为92.6个月 vs 47.6个月,移植肝组织病理学评估为93.3个月 vs 55.1个月。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND. LI-RADS has been investigated primarily in terms of detection of hepatocellular carcinoma (HCC), with less attention given to its performance, particularly on CT, in determining eligibility for liver transplant (LT). OBJECTIVE. The purpose of our study was to assess the performance of LI-RADS version 2018 (v2018) on CT for the diagnosis of HCC and determination of LT eligibility according to the Milan criteria (MC). METHODS. This retrospective study included 136 patients (110 men, 26 women; mean age, 53.9 ± 8.1 [SD] years) at high-risk for HCC who underwent liver protocol CT within 3 months before LT between January 2010 and December 2018. Two radiologists independently reviewed CT examinations using LI-RADS v2018; Organ Procurement and Transplantation Network (OPTN) classes were constructed from the LI-RADS interpretations. Histopathologic analysis of liver explants served as the reference standard for determining the presence of HCC and LT eligibility based on MC. Diagnostic performance was evaluated. Overall survival (OS) was assessed based on medical record review. RESULTS. Based on histopathologic evaluation of liver explants in the 136 patients, 27 patients had no malignancy, 77 were eligible for LT due to HCC within MC, and 32 were unsuitable for LT (i.e., HCC beyond MC in 16 patients, HCC with macrovascular invasion in 12, non-HCC malignancy in four). LR-5 exhibited per-lesion sensitivity and PPV for HCC of 55.9% and 92.8%, respectively, for reader 1 and 39.8% and 86.5% for reader 2. When considering LR-5 observations to represent HCC in assessing MC, LI-RADS had accuracy for determining LT eligibility of 92.7% for reader 1 and 85.3% for reader 2; OPTN criteria had accuracy for determining LT eligibility of 89.0% for reader 1 and 84.4% for reader 2. Five-year OS for patients within MC versus 5-year OS for patients unsuitable for LT was 92.2 months versus 56.0 months for LI-RADS, 92.6 months versus 47.6 months for OPTN criteria, and 93.3 months versus 55.1 months for histopathologic assessment of liver explants. CONCLUSION. LI-RADS v2018, as evaluated on CT in high-risk patients, shows high PPV for HCC detection and high accuracy for determining LT eligibility based on MC. LT eligibility based on preoperative LI-RADS evaluation is associated with post-LT survival. CLINICAL IMPACT. These findings support the use of LI-RADS on CT in assessing eligibility in patients who are candidates for LT.
引用
- Bae JS, Lee DH, Lee SM, et al. Performance of LI-RADS Version 2018 on CT for Determining Eligibility for Liver Transplant According to Milan Criteria in Patients at High Risk for Hepatocellular Carcinoma. AJR Am J Roentgenol. 2022. PMID: 35138137. doi:10.2214/AJR.21.27186
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。